2014
Comorbidity, Chemotherapy Toxicity, and Outcomes Among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer on a Clinical Trial: CALGB 49907 and CALGB 361004 (Alliance)
Klepin HD, Pitcher BN, Ballman KV, Kornblith AB, Hurria A, Winer EP, Hudis C, Cohen HJ, Muss HB, Kimmick GG. Comorbidity, Chemotherapy Toxicity, and Outcomes Among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer on a Clinical Trial: CALGB 49907 and CALGB 361004 (Alliance). JCO Oncology Practice 2014, 10: e285-e292. PMID: 25074878, PMCID: PMC4161730, DOI: 10.1200/jop.2014.001388.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic AgentsBreast NeoplasmsCapecitabineChemotherapy, AdjuvantComorbidityDeoxycytidineDisease-Free SurvivalFemaleFluorouracilHumansKaplan-Meier EstimateMultivariate AnalysisProportional Hazards ModelsQuality of LifeRegression AnalysisSurveys and QuestionnairesTreatment OutcomeConceptsOverall survivalAdjuvant chemotherapyBurden scoreBreast cancerOlder womenShorter OSClinical trialsEarly-stage breast cancerCox proportional hazards modelStandard adjuvant chemotherapyNumber of comorbiditiesHazard of deathPhysical health subscaleOlder Americans ResourcesProportional hazards modelCALGB 49907Chemotherapy toxicityReceptor statusComorbid conditionsTumor sizeHealth subscaleGrade 3ComorbiditiesCommon conditionHazards model
2008
The impact of sharing results of a randomized breast cancer clinical trial with study participants
Partridge AH, Wolff AC, Marcom PK, Kaufman PA, Zhang L, Gelman R, Moore C, Lake D, Fleming GF, Rugo HS, Atkins J, Sampson E, Collyar D, Winer EP. The impact of sharing results of a randomized breast cancer clinical trial with study participants. Breast Cancer Research And Treatment 2008, 115: 123-129. PMID: 18543100, DOI: 10.1007/s10549-008-0057-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAnxietyChemotherapy, AdjuvantClinical Trials, Phase III as TopicCommunicationData CollectionHumansMiddle AgedPatient Education as TopicPatient SatisfactionPerceptionRandomized Controlled Trials as TopicRecurrenceRegression AnalysisResearch DesignTrastuzumabConceptsCancer clinical trialsClinical trialsStudy participantsBreast cancer clinical trialsCooperative group trialsSubset of womenResults One hundredClinical trial participantsPercent of participantsRecurrent diseasePatients' perceptionsGroup trialsTrial participantsFavorable responsePsychosocial supportLogistic regressionOne hundredTrialsPatientsTrastuzumabStudy resultsParticipantsTreatmentPreliminary study resultsAnxiety
2007
Long‐term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer
Kornblith AB, Powell M, Regan MM, Bennett S, Krasner C, Moy B, Younger J, Goodman A, Berkowitz R, Winer E. Long‐term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psycho-Oncology 2007, 16: 895-903. PMID: 17245695, DOI: 10.1002/pon.1146.Peer-Reviewed Original ResearchConceptsPsychosocial adjustmentLong-term psychosocial adjustmentWorse adaptationBattery of measuresCancer survivorsFear of recurrenceOlder survivorsYoung survivorsYoung cancer survivorsCancer-related problemsEndometrial cancer survivorsBetter adjustmentDepression ScaleSexual problemsHospital AnxietyLong-term survivorsTreatment completionPhysical functioningOlder breastSurvivorsEndometrial cancerStudy entryAdjustmentMost differencesAnxiety
1994
Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
Rowinsky EK, Noe DA, Trump DL, Winer EP, Lucas VS, Wargin WA, Hohneker JA, Lubejko B, Sartorius SE, Ettinger DS. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. Journal Of Clinical Oncology 1994, 12: 1754-63. PMID: 8083697, DOI: 10.1200/jco.1994.12.9.1754.Peer-Reviewed Original ResearchConceptsMaximum-tolerated doseOral administrationOral formulationOral vinorelbineGrade 3Large first-pass effectLower starting doseSemisynthetic vinca alkaloidChronic oral administrationHepatic blood flowPhase II evaluationPharmacokinetic studyDivided-dose scheduleMaximum plasma concentrationFirst-pass effectSteady-state volumeGelatin capsulesPlasma drug dispositionPharmacologic exposuresPrincipal toxicityStarting doseDose escalationOral dosesOral doseCancer patients